SPRY
ARS Pharmaceuticals, Inc.
Healthcare — Biotechnology
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Strong Buy
1.0 / 5
4 analysts
$4.12
$-0.19 (-4.41%)
Target:
$29.25
(610.0%)
Price History
52-Week Range
Sign in to add SPRY to a watchlist or set price alerts.
Fundamentals
| Market Cap | $800.88M |
| P/E Ratio (TTM) | - |
| Forward P/E | -9.45 |
| EPS (TTM) | $-2.00 |
| Dividend Yield | - |
| Profit Margin | -200.00% |
| Revenue Growth | 184.50% |
| ROE | -136.40% |
| Debt/Equity | 279.24 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $29.25 |
| Analysts | 4 |
| Next Earnings | Aug 13, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 36.1 |
| Beta | 0.83 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $18.63 |
| 52-Week Low | $6.66 |
| 50-Day Avg | $8.70 |
| 200-Day Avg | $9.33 |
| Avg Volume | $1.80M |
| Volume | 11.6K |
Performance Analysis
BULLISHSPRY shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($6.66), which could present a value opportunity.
~
RSI at 36.1 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Strong revenue growth of 184.5% year-over-year.
-
Operating at a loss with -200.0% margin.
+
Wall Street consensus is "Strong Buy" from 4 analysts.
+
Average analyst target of $29.25 implies 610.0% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:32 UTC
Back to Screener Export Report